New iron chelators in anthracycline-induced cardiotoxicity
- 19 April 2007
- journal article
- review article
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 7 (2) , 145-150
Abstract
The use of anthracycline anticancer drugs is limited by a cumulative, dose-dependent cardiac toxicity. Iron chelation has long been considered as a promising strategy to limit this unfavorable side effect, either by restoring the disturbed cellular iron homeostasis or by removing redox-active iron, which may promote anthracycline-induced oxidative stress. Aroylhydrazone lipophilic iron chelators have shown promising results in the rabbit model of daunorubicin-induced cardiomyopathy as well as in cellular models. The lack of interference with the antiproliferative effects of the anthracyclines also favors their use in clinical settings. The dose, however, should be carefully titrated to prevent iron depletion, which apparently also applies for other strong iron chelators. We have shown that a mere ability of a compound to chelate iron is not the sole determinant of a good cardioprotector and the protective potential does not directly correlate with the ability of the chelators to prevent hydroxyl radical formation. These findings, however, do not weaken the role of iron in doxorubicin cardiotoxicity as such, they rather appeal for further investigations into the molecular mechanisms how anthracyclines interact with iron and how iron chelation may interfere with these processes.Keywords
This publication has 22 references indexed in Scilit:
- A Pro-Chelator Triggered by Hydrogen Peroxide Inhibits Iron-Promoted Hydroxyl Radical FormationJournal of the American Chemical Society, 2006
- HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic studyJournal of Chromatography B, 2006
- The role of reactive oxygen and nitrogen species in cellular iron metabolismFree Radical Research, 2006
- SIH—a novel lipophilic iron chelator—protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell deathJournal of Molecular and Cellular Cardiology, 2005
- Development of high‐performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo studyJournal of Separation Science, 2005
- Rabbit Model for in Vivo Study of Anthracycline-Induced Heart Failure and for the Evaluation of Protective AgentsEuropean Journal of Heart Failure, 2004
- The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicinFree Radical Biology and Medicine, 2003
- Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in ratsProceedings of the National Academy of Sciences, 2002
- Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interactionJournal of Laboratory and Clinical Medicine, 1996
- Comparison of Different Iron Chelators as Protective Agents Against Acute Doxorubicin-induced CardiotoxicityJournal of Molecular and Cellular Cardiology, 1994